Showing 3031-3040 of 6035 results for "".
- Three Potential Futures For COVID-19: Recurring Small Outbreaks, a Monster Wave, or a Persistent Crisishttps://modernod.com/news/three-potential-futures-for-covid-19-recurring-small-outbreaks-a-monster-wave-or-a-persistent-crisis/2477716/As epidemiologists attempt to scope out what COVID-19 has in store for the U.S. this summer and beyond, they see several potential futures, differing by how often and how severely the no-longer-new coronavirus continues to wallop humankind, according to a Stat News
- AbbVie, Allergan Gain US Antitrust Clearance for Dealhttps://modernod.com/news/abbvie-allergan-gain-us-antitrust-clearance-for-deal/2477714/The US Federal Trade Commission (FTC) accepted the proposed consent order in connection with AbbVie’s pending $63-billion acquisition of Allergan, the companies announced. The FTC’s decision means that all required antitrust clearances needed for the merger have now been obtained.
- AI-Supported Test Can Detect Glaucoma Progression 18 Months Earlierhttps://modernod.com/news/ai-supported-test-can-detect-glaucoma-progression-18-months-earlier/2477706/A new test can detect glaucoma progression 18 months earlier than the current gold standard method, according to results from a clinical trial sponsored by the University College London (UCL). The technology, supported by an artificial intelligence (AI) algorithm, could help accelerate cli
- SightGlass Vision Announces R&D Webinar Featuring Leading Myopia Expertshttps://modernod.com/news/sightglass-vision-announces-rd-webinar-featuring-leading-myopia-experts/2477704/SightGlass Vision announced it will hold an R&D webinar to discuss the science of and latest research in myopia, as well as provide an overview about the clinical development and commercialization program for the company’s novel glasses designed to slow the progression of myopia in chil
- CooperVision Extends Deadline for Science and Technology Awards Proposalshttps://modernod.com/news/coopervision-extends-deadline-for-science-and-technology-awards-proposals/2477688/CooperVision has extended the submission deadline for its
- AAO, ASCRS, and OOSS Develop Checklist for Reopening Ophthalmic Surgery Centershttps://modernod.com/news/ooss-aao-and-ascrs-develop-checklist-for-reopening-ophthalmic-surgery-centers/2477669/To support the safe reopening of care, the American Academy of Ophthalmology (AAO), American Society of Cataract and Refractive Surgery (ASCRS), and the Outpatient Ophthalmic Surgery Society (OOSS), developed a checklist<
- European Leaders, WHO Team Up on $8 Billion Pandemic Vaccine Responsehttps://modernod.com/news/european-leaders-who-team-up-on-8b-pandemic-vaccine-response/2477664/The leaders of Germany and France and a host of other EU countries and groups have come together with the World Health Organization (WHO) for an $8 billion push for a new vaccine against COVID-19, according to a FierceBiotech
- Ocular Therapeutix Announces Topline Results of Phase 3 Clinical Trial of Dextenza for Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-announces-topline-results-of-phase-3-clinical-trial-of-dextenza-for-allergic-conjunctivitis/2477659/Ocular Therapeutix announced topline results from its phase 3 clinical trial to evaluate the safety and efficacy of Dextenza for the treatment of ocular itching associated with allergic conjunctivitis (AC). In the phase 3 trial, Dextenza met all prespecified primary endpoints as demonstrated by a
- SightGlass Vision Unveils Topline Data From Study of Novel Eyeglasses Designed to Control Myopia in Childrenhttps://modernod.com/news/sightglass-vision-unveils-topline-data-from-study-of-novel-eyeglasses-designed-to-control-myopia-in-children/2477653/SightGlass Vision announced topline data from the company’s pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children. Results from a planned 12-month interim analysis of the CYPRESS clinical study (NCT03623074) demonstrated a reduction in myopia p
- Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeuticshttps://modernod.com/news/q-biomed-initiates-rapid-development-of-novel-covid-19-therapeutics/2477631/Q BioMed announced that together with its technology partner, Mannin Research, they are accelerating the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and other viral infections. This novel drug program is being evaluated by government pro